BR112013011715A2 - formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil - Google Patents
formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metilInfo
- Publication number
- BR112013011715A2 BR112013011715A2 BR112013011715A BR112013011715A BR112013011715A2 BR 112013011715 A2 BR112013011715 A2 BR 112013011715A2 BR 112013011715 A BR112013011715 A BR 112013011715A BR 112013011715 A BR112013011715 A BR 112013011715A BR 112013011715 A2 BR112013011715 A2 BR 112013011715A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkoxyimidazol
- biphenyl
- carboxylic acid
- crystalline forms
- methyl carboxylic
- Prior art date
Links
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title 1
- 235000010290 biphenyl Nutrition 0.000 title 1
- 239000004305 biphenyl Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41201110P | 2010-11-10 | 2010-11-10 | |
| PCT/US2011/059895 WO2012064807A1 (en) | 2010-11-10 | 2011-11-09 | Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013011715A2 true BR112013011715A2 (pt) | 2017-10-31 |
Family
ID=45003086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013011715A BR112013011715A2 (pt) | 2010-11-10 | 2011-11-09 | formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8362060B2 (https=) |
| EP (1) | EP2638017B1 (https=) |
| JP (2) | JP2013542258A (https=) |
| KR (1) | KR20130130730A (https=) |
| CN (1) | CN103189362B (https=) |
| AR (1) | AR083828A1 (https=) |
| AU (1) | AU2011326622B2 (https=) |
| BR (1) | BR112013011715A2 (https=) |
| CA (1) | CA2812598A1 (https=) |
| CO (1) | CO6741224A2 (https=) |
| ES (1) | ES2567721T3 (https=) |
| IL (1) | IL225303A0 (https=) |
| MX (1) | MX2013005165A (https=) |
| NZ (1) | NZ609804A (https=) |
| PH (1) | PH12013500945A1 (https=) |
| RU (1) | RU2013126403A (https=) |
| SG (1) | SG189448A1 (https=) |
| TW (1) | TW201300366A (https=) |
| WO (1) | WO2012064807A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| CN106810542B (zh) * | 2015-11-30 | 2021-03-09 | 苏州开拓药业股份有限公司 | 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法 |
| EP4337638A1 (en) * | 2021-05-11 | 2024-03-20 | Astex Pharmaceuticals, Inc. | Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006027680A1 (en) | 2004-09-10 | 2006-03-16 | Pfizer Limited | 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| WO2007106708A2 (en) | 2006-03-10 | 2007-09-20 | Novartis Ag | Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril |
| TWI448284B (zh) * | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| TW201014830A (en) * | 2008-09-30 | 2010-04-16 | Theravance Inc | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
| TWI545114B (zh) * | 2009-09-29 | 2016-08-11 | 施萬生物製藥研發Ｉｐ有限責任公司 | 製備聯苯基咪唑化合物之方法 |
| US8399501B2 (en) | 2010-03-04 | 2013-03-19 | Theravance, Inc. | Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof |
-
2011
- 2011-11-09 BR BR112013011715A patent/BR112013011715A2/pt not_active IP Right Cessation
- 2011-11-09 AU AU2011326622A patent/AU2011326622B2/en not_active Ceased
- 2011-11-09 EP EP11785872.0A patent/EP2638017B1/en active Active
- 2011-11-09 CA CA2812598A patent/CA2812598A1/en not_active Abandoned
- 2011-11-09 CN CN201180053069.5A patent/CN103189362B/zh not_active Expired - Fee Related
- 2011-11-09 PH PH1/2013/500945A patent/PH12013500945A1/en unknown
- 2011-11-09 JP JP2013538839A patent/JP2013542258A/ja active Pending
- 2011-11-09 ES ES11785872.0T patent/ES2567721T3/es active Active
- 2011-11-09 NZ NZ609804A patent/NZ609804A/en not_active IP Right Cessation
- 2011-11-09 KR KR1020137014134A patent/KR20130130730A/ko not_active Withdrawn
- 2011-11-09 RU RU2013126403/04A patent/RU2013126403A/ru not_active Application Discontinuation
- 2011-11-09 WO PCT/US2011/059895 patent/WO2012064807A1/en not_active Ceased
- 2011-11-09 US US13/292,370 patent/US8362060B2/en not_active Expired - Fee Related
- 2011-11-09 MX MX2013005165A patent/MX2013005165A/es unknown
- 2011-11-09 SG SG2013029178A patent/SG189448A1/en unknown
- 2011-11-10 TW TW100141108A patent/TW201300366A/zh unknown
- 2011-11-10 AR ARP110104201A patent/AR083828A1/es unknown
-
2012
- 2012-12-19 US US13/720,395 patent/US8802709B2/en not_active Expired - Fee Related
-
2013
- 2013-03-18 IL IL225303A patent/IL225303A0/en unknown
- 2013-05-03 CO CO13111802A patent/CO6741224A2/es unknown
-
2014
- 2014-06-27 US US14/317,060 patent/US9249105B2/en not_active Expired - Fee Related
-
2015
- 2015-09-04 JP JP2015174397A patent/JP2016028061A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR083828A1 (es) | 2013-03-27 |
| CO6741224A2 (es) | 2013-08-30 |
| PH12013500945A1 (en) | 2013-07-08 |
| TW201300366A (zh) | 2013-01-01 |
| AU2011326622B2 (en) | 2014-12-18 |
| HK1187919A1 (zh) | 2014-04-17 |
| EP2638017B1 (en) | 2016-01-27 |
| RU2013126403A (ru) | 2014-12-20 |
| US20120115920A1 (en) | 2012-05-10 |
| JP2016028061A (ja) | 2016-02-25 |
| MX2013005165A (es) | 2013-07-05 |
| US9249105B2 (en) | 2016-02-02 |
| US8362060B2 (en) | 2013-01-29 |
| US20130267573A1 (en) | 2013-10-10 |
| KR20130130730A (ko) | 2013-12-02 |
| ES2567721T3 (es) | 2016-04-26 |
| JP2013542258A (ja) | 2013-11-21 |
| CN103189362A (zh) | 2013-07-03 |
| NZ609804A (en) | 2015-02-27 |
| CA2812598A1 (en) | 2012-05-18 |
| AU2011326622A1 (en) | 2013-04-04 |
| US20150133518A1 (en) | 2015-05-14 |
| IL225303A0 (en) | 2013-06-27 |
| WO2012064807A1 (en) | 2012-05-18 |
| US8802709B2 (en) | 2014-08-12 |
| CN103189362B (zh) | 2015-03-11 |
| EP2638017A1 (en) | 2013-09-18 |
| SG189448A1 (en) | 2013-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013937A2 (pt) | compostos de ácido carboxílico | |
| BR112014029261A2 (pt) | compostos de ácido carboxílico | |
| EP2576492A4 (en) | TREPROSTINILHERSTELLUNG | |
| EP2742051A4 (en) | AMORPHIC FORM OF DOLUTEGRAVIR | |
| EP2536276A4 (en) | NEW BEXAROTE ANALOGUE | |
| DK2935563T3 (da) | Biologisk fremgangsmåde til fremstilling af en dicarboxylfedtsyre | |
| HUE035861T2 (hu) | Egy pleuromutilin kristályos formája | |
| BR112012000890A2 (pt) | formas de base livre cristalina de um composto bifenil | |
| ZA201306560B (en) | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | |
| PL2558435T3 (pl) | Krystaliczny rombowy mebutynian ingenolu | |
| LTPA2020526I1 (lt) | 2-Acilaminotiazolo junginio kristalai | |
| DE112012001776A5 (de) | Drehmomentwandler | |
| ZA201401901B (en) | Guanidinobenzoic acid compound | |
| CL2014000290A1 (es) | Uso y composicion agroquimica de dibutilamidas de acido carboxilico | |
| BRPI1013620A2 (pt) | método para produzir um composto de ácido cetomalônico | |
| EP2784924A4 (en) | AC CONVERTER CIRCUIT | |
| SMT201400109B (it) | Composto cicloesanico | |
| BR112013002589A2 (pt) | valsatana altamente cristalina | |
| DK2438012T3 (da) | Fremgangsmåde til fremstilling af en sammensætning omfattende meso-vinsyre | |
| BR112013011715A2 (pt) | formas cristalinas de um ácido carboxílico bifenil alcoximidazol-1-il metil | |
| BR112012029415A2 (pt) | processos para a produção de pirrolidonas | |
| BR112013015002A2 (pt) | método para obter um composto | |
| BR112012029402A2 (pt) | processos para a produção de pirrolidonas | |
| BR112013015003A2 (pt) | método para obter um composto | |
| DK2848612T3 (da) | Fremgangsmåde til fremstilling af en substitueret benzoesyreforbindelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/412,011, REIVINDICADA NO PCT/US2011/059895, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("THERAVANCE, INC") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E, MESMO APOS A ELABORACAO DE EXIGENCIA PARA TAL, NAO FOI REGULARIZADO O DOCUMENTO COMPROBATORIO DE CESSAO DA CITADA PRIORIDADE REIVINDICADA ACOMPANHADO DE SUA RESPECTIVA TRADUCAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E N |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B25B | Requested transfer of rights rejected |
Owner name: THERAVANCE, INC (US) |